Tests whole-body heating with two drugs in men with spreading prostate cancer
Tests whole-body heating with two drugs in men with spreading prostate cancer.
Plain-language title generated from the registry record
Registry title: Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06249750, who can take part
Where in China
- Zhejiang HospitalHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pengyuan Liu
- Trial code
- NCT06249750
- Record updated
- 8 February 2024
- Original description
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.Read full original descriptionShow less
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
Inclusion: Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC; Complete and reliable medical history and medical records; No other primary tumors except CRPC; Blood tests, liver function, renal function and electrocardiogram are basically normal; Patients with ECOG score 0~3, aged ≥18 years and <90 years old; Patients with good compliance, able to accept regular follow-up.
Exclusion: Those who have recently participated in other clinical trials and have not passed the washout period; History of malignant tumor other than PC within the past 5 years; Accompanied by severe underlying diseases that cannot tolerate this therapy; With acute diseases, such as acute infection, active bleeding; Those who have a history of allergy to the drugs used in the trial; Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study; Those who cannot tolerate systemic heat stress, such as claustrophobic patients; Patients with other reasons for not being able to be enrolled in the study, according to the study doctor.